We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

95 hedge funds and large institutions have $167M invested in Aratana Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 27

13% more call options, than puts

Call options by funds: $18K | Put options by funds: $16K

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3% less funds holding

Funds holding: 9895 (-3)

5% less capital invested

Capital invested by funds: $176M → $167M (-$8.86M)

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

Holders
95
Holders Change
-3
Holders Change %
-3.06%
% of All Funds
2.53%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
16
Increased
32
Reduced
27
Closed
18
Calls
$18K
Puts
$16K
Net Calls
+$2K
Net Calls Change
-$11K
Name Holding Trade Value Shares
Change
Change in
Stake
KCM
26
Kornitzer Capital Management
Kansas
$1M -$432K -115,000 -39%
Manulife (Manufacturers Life Insurance)
27
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$933K -$699K -185,955 -51%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$874K +$550K +146,206 +1,214%
CCI
29
Columbus Circle Investors
$795K +$73.9K +19,667 +16%
TCIM
30
TIAA CREF Investment Management
New York
$770K +$152K +40,360 +41%
CA
31
Continental Advisors
Utah
$687K +$468K +124,399 New
WCM
32
Westend Capital Management
California
$680K +$126K +33,410 +37%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$647K -$48.2K -12,818 -10%
HLA
34
Hamilton Lane Advisors
Pennsylvania
$617K
BIM
35
BlackRock Investment Management
Delaware
$596K +$6.93K +1,843 +2%
UBS AM
36
UBS AM
Illinois
$589K -$151K -40,251 -27%
T. Rowe Price Associates
37
T. Rowe Price Associates
Maryland
$566K
AP
38
AlpInvest Partners
Netherlands
$552K
WMSA
39
Weiss Multi-Strategy Advisers
New York
$502K
GA
40
Geneva Advisors
Illinois
$396K +$156K +41,480 +137%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$352K +$33.1K +8,800 +16%
AQR Capital Management
42
AQR Capital Management
Connecticut
$339K -$14.3K -3,792 -6%
Dimensional Fund Advisors
43
Dimensional Fund Advisors
Texas
$334K +$61.3K +16,300 +37%
Charles Schwab
44
Charles Schwab
California
$295K
RAM
45
Redmond Asset Management
Virginia
$295K +$201K +53,472 New
JHIU
46
Janus Henderson Investors US
Colorado
$293K +$199K +53,061 New
TA
47
Teachers Advisors
New York
$291K +$33.7K +8,956 +20%
TC
48
TFS Capital
Pennsylvania
$290K -$74.2K -19,748 -27%
NFA
49
Nationwide Fund Advisors
Ohio
$286K
Mariner
50
Mariner
Kansas
$285K +$52.8K +14,031 +37%

PETX Hedge Fund Activity: Q1 2016 in Review

95 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q1 2016, worth a combined $167M — down 5% from $176M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PETX and 16 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 32 added.

The largest buyer was Franklin Resources, adding an estimated $3.9M. The largest seller was Wellington Management Group, cutting an estimated $5.14M.

  • 95 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q1 2016, down from 98 in Q4 2015.
  • Funds reported $167M of Aratana Therapeutics, Inc. stock for Q1 2016, down 5% quarter-over-quarter.
  • 16 funds opened new Aratana Therapeutics, Inc. positions in Q1 2016 and 18 closed out, a net change of -2 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q1 2016 was Franklin Resources, an estimated $3.9M added.
  • The largest Aratana Therapeutics, Inc. seller in Q1 2016 was Wellington Management Group, an estimated $5.14M sold.

Based on aggregated 13F filings for Q1 2016.